Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 4
2017 3
2018 12
2019 14
2020 18
2021 24
2022 20
2023 27
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
Mirogabalin: could it be the next generation gabapentin or pregabalin?
Kim JY, Abdi S, Huh B, Kim KH. Kim JY, et al. Korean J Pain. 2021 Jan 1;34(1):4-18. doi: 10.3344/kjp.2021.34.1.4. Korean J Pain. 2021. PMID: 33380563 Free PMC article. Review.
Pregabalin, which followed gabapentin, was developed with the benefit of rapid peak blood concentration and better bioavailability. Mirogabalin besylate (DS-5565, Tarlige()) shows greater sustained analgesia due to a high affinity to, and slow dissociation fr …
Pregabalin, which followed gabapentin, was developed with the benefit of rapid peak blood concentration and better bioavailability. Mirog …
Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Okubo Y, Nakamura J, Takasumi M, Hashimoto M, Kato T, Kobashi R, Hikichi T, Ohira H. Sugimoto M, et al. BMC Cancer. 2021 Dec 9;21(1):1319. doi: 10.1186/s12885-021-09069-9. BMC Cancer. 2021. PMID: 34886831 Free PMC article.
Among them, 34 patients were diagnosed with CIPN. Thirteen patients were treated with mirogabalin (mirogabalin group), and twenty-one patients were treated with pregabalin (pregabalin group). ...CONCLUSIONS: Although both mirogabalin and pregabalin were effec …
Among them, 34 patients were diagnosed with CIPN. Thirteen patients were treated with mirogabalin (mirogabalin group), and twe …
Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia.
Ushida T, Katayama Y, Hiasa Y, Nishihara M, Tajima F, Katoh S, Tanaka H, Maeda T, Furusawa K, Richardson M, Kakehi Y, Kikumori K, Kuroha M. Ushida T, et al. Neurology. 2023 Mar 14;100(11):e1193-e1206. doi: 10.1212/WNL.0000000000201709. Epub 2022 Dec 14. Neurology. 2023. PMID: 36517235 Free PMC article. Clinical Trial.
METHODS: This randomized, double-blind, placebo-controlled, phase 3 study investigated mirogabalin efficacy and safety for the treatment of CNeP in patients with traumatic SCI. ...Most treatment-emergent adverse events were mild; no serious adverse drug reactions were repo …
METHODS: This randomized, double-blind, placebo-controlled, phase 3 study investigated mirogabalin efficacy and safety for the treatm …
Efficacy of Mirogabalin (DS-5565) on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase II Proof-of-Concept Study.
Merante D, Rosenstock J, Sharma U, Feins K, Hsu C, Vinik A; DS-5565-A-U201 US Phase 2 Study Investigators. Merante D, et al. Pain Med. 2017 Nov 1;18(11):2198-2207. doi: 10.1093/pm/pnw342. Pain Med. 2017. PMID: 28371941 Clinical Trial.
OBJECTIVE: To evaluate the effects of mirogabalin on patient-reported pain and sleep interference in diabetic peripheral neuropathic pain (DPNP). ...At end of treatment, the percentage of subject with PGIC status of "much improved or better" was greater in all mirogabal …
OBJECTIVE: To evaluate the effects of mirogabalin on patient-reported pain and sleep interference in diabetic peripheral neuropathic …
Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients.
Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Baba M, et al. J Diabetes Investig. 2019 Sep;10(5):1299-1306. doi: 10.1111/jdi.13013. Epub 2019 Feb 28. J Diabetes Investig. 2019. PMID: 30672128 Free PMC article. Clinical Trial.
CONCLUSIONS: Mirogabalin relieved DPNP in a dose-dependent manner; mirogabalin 30 mg/day showed statistically significant pain relief (vs placebo) in Asian DPNP patients. All doses of mirogabalin tested were well tolerated....
CONCLUSIONS: Mirogabalin relieved DPNP in a dose-dependent manner; mirogabalin 30 mg/day showed statistically significant pain …
Switching From Pregabalin to Mirogabalin in Patients with Peripheral Neuropathic Pain: A Multi-Center, Prospective, Single-Arm, Open-Label Study (MIROP Study).
Kimura Y, Yamaguchi S, Suzuki T, Kato J, Chiba S, Hirakawa N, Yamaguchi K, Tanabe Y, Takatsuna H, Kenyoshi Y, Shiosakai K, Sakai M, Iseki M. Kimura Y, et al. Pain Ther. 2021 Jun;10(1):711-727. doi: 10.1007/s40122-021-00255-y. Epub 2021 Apr 15. Pain Ther. 2021. PMID: 33856660 Free PMC article.
INTRODUCTION: Mirogabalin, which is a selective ligand of the alpha(2)delta subunit of voltage-gated Ca(2+) channels, was recently approved in Japan for peripheral neuropathic pain. The alpha(2)delta ligands, including mirogabalin and pregabalin, are associated with …
INTRODUCTION: Mirogabalin, which is a selective ligand of the alpha(2)delta subunit of voltage-gated Ca(2+) channels, was recently ap …
Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study.
Nikaido T, Takatsuna H, Tabata S, Shiosakai K, Nakatani T, Konno SI. Nikaido T, et al. Pain Ther. 2022 Dec;11(4):1195-1214. doi: 10.1007/s40122-022-00410-z. Epub 2022 Jul 20. Pain Ther. 2022. PMID: 35857196 Free PMC article.
CONCLUSIONS: The addition of mirogabalin to NSAIDs improved VAS, EQ-5D-5L, and PGIC. The main TEAEs were somnolence and dizziness. The addition of mirogabalin to NSAIDs improved peripheral neuropathic pain associated with LSS and raised no new safety concerns. ...
CONCLUSIONS: The addition of mirogabalin to NSAIDs improved VAS, EQ-5D-5L, and PGIC. The main TEAEs were somnolence and dizziness. Th …
Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study.
Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D; DS5565-A-U201 US Phase II Study Investigators. Vinik A, et al. Diabetes Care. 2014 Dec;37(12):3253-61. doi: 10.2337/dc14-1044. Epub 2014 Sep 17. Diabetes Care. 2014. PMID: 25231896 Clinical Trial.
OBJECTIVE: We aimed to identify doses of mirogabalin (DS-5565) providing clinically meaningful efficacy with manageable side effects for treatment of diabetic peripheral neuropathic pain (DPNP). ...Mirogabalin may be a promising new treatment option fo …
OBJECTIVE: We aimed to identify doses of mirogabalin (DS-5565) providing clinically meaningful efficacy with manageable …
The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids.
Tang H, Lu J, Duan Y, Li D. Tang H, et al. Mediators Inflamm. 2023 Apr 28;2023:4893436. doi: 10.1155/2023/4893436. eCollection 2023. Mediators Inflamm. 2023. PMID: 37152369 Free PMC article. Review.
METHODS: A review was carried out on a series of platforms, such as PubMed, MEDLINE, and Scopus, up to December 2021 using the keywords as follows: "mirogabalin OR mirogabalin besylate OR Tarlige OR DS-5565" AND "neuropathic pain OR Neuropathy." ... …
METHODS: A review was carried out on a series of platforms, such as PubMed, MEDLINE, and Scopus, up to December 2021 using the keywords as f …
Mirogabalin: First Global Approval.
Deeks ED. Deeks ED. Drugs. 2019 Mar;79(4):463-468. doi: 10.1007/s40265-019-01070-8. Drugs. 2019. PMID: 30778848 Review.
Mirogabalin besylate (hereafter mirogabalin) [Tarlige()] is an orally administered gabapentinoid developed by Daiichi Sankyo for the treatment of peripheral neuropathic pain (PNP), including diabetic PNP and post-herpetic neuralgia. ...This article summarizes the mi …
Mirogabalin besylate (hereafter mirogabalin) [Tarlige()] is an orally administered gabapentinoid developed by Daiichi Sankyo f …
111 results